|| Print ||
|Saturday, December 01, 2007|
It’s a tricky thing to talk up a mouse without getting cheesy. But this little guy, by all appearances a normal rodent, has a human liver inside of it, making it a real-life mighty mouse worth at least five grand. Markus Grompe of the Oregon Stem Cell Center at Oregon Health & Science University is breeding more of this star in hopes of revolutionizing the way drugs are tested. The mouse’s liver is infected with disease and then healthy human liver cells are transplanted into it; these human cells thrive until the liver is only 10% mouse. The new liver allows the mice to metabolize and excrete medications like a human. Pharmaceutical companies testing medication toxicity and searching for disease cures are interested because testing on this mouse is like testing on real human liver cells, which are hard to come by. Previous technology only allowed for an inconsequential number of human cells in mice, and a more recent Japanese version can’t control the liver disease or stop healthy mouse liver cells from regenerating. Those mice have shorter life spans and are difficult to breed, which makes Grompe optimistic that he’s developed a big seller. With the Japanese mice selling for $5,000 each, Grompe could be holding a small, furry fortune in his hands. AMBER NOBE
Monday, November 10, 2014
BY KIM MOORE | OB RESEARCH EDITOR
A market for low-carbon transportation fuels has a chance to flourish in Oregon if regulators adopt the second phase of the state’s Clean Fuels Program.
Wednesday, October 22, 2014
We didn’t intend this issue to have an election season theme. But politics has a way of seeping into the cracks and fissures.
Sunday, October 12, 2014
BY LINDA BAKER
Cylvia Hayes, tabloid vs. watchdog journalism and the looming threat of a Cascadia earthquake.
Wednesday, October 22, 2014
BY JOE ROJAS-BURKE & KIM MOORE
Oregon Business reports on the visa squeeze, the skills gap and foreign-born residents who are revitalizing rural Oregon.
Thursday, October 02, 2014
Oregon Business magazine has named the sixth annual 100 Best Nonprofits to Work for in Oregon.
Thursday, November 20, 2014
BY JASON NORRIS | OB CONTRIBUTOR
Each month for Oregon Business, we assess factors that are shaping current capital market activity—and what they mean to investors. Here we take a look at two major developments regarding possible rollbacks of the Affordable Care Act (ACA).
Wednesday, October 15, 2014
BY DIANE BUISMAN
Some common misconceptions employers have about marijuana.
|A Complex Portrait: Immigration, Jobs and the Economy|
|Woman of Steel|
|Kill the Meeting|
|Price of already-built homes in Seattle area drops|
|Apple hits record-high value|
|Fed's ability to regulate questioned|
|Budweiser to move away from Clydesdales|
|Mergers lucrative for departing CEOs, but not necessarily shareholders|
|Senators ask, but get no real answers regarding safety from air bag executives|
|Senate investigation says Wall Street misused commodities businesses|
Is your business ready to join us in the call for action? This opening panel includes Oregon businesses who will discuss why they signed the Oregon Climate Declaration, the investments they are making to reduce carbon emissions, and how their actions are affecting their companies.
Get ready for two days of special events produced with the EPA, Portland Timbers and ISOS before and after the GoGreen Conference on October 16.
Plenty of employers seem “dazed and confused” after the recent vote to legalize marijuana. In light of Measure 91 passing, what are some issues for private-sector Oregon employers to consider?
Rotary’s Oregon Ethics in Business aims to raise consciousness about business ethics by honoring exceptional companies.
Barran Liebman’s annual employment law seminar is an industry classic.
Is my drug-free workplace policy up in smoke?
More than 400 "Change Makers" will gather to invest in a socially sustainable community.